SWIFT-2
Trial question
What is the role of depemokimab in patients with severe eosinophilic asthma?
Study design
Multi-center
Double blinded
RCT
Population
Characteristics of study participants
63.0% female
37.0% male
N = 380
380 patients (241 female, 139 male).
Inclusion criteria: patients with severe eosinophilic asthma.
Key exclusion criteria: receiving biologic therapy as part of maintenance therapy; anti-IL-5 antibody therapy in the past 12 months; known pre-existing, clinically important lung condition other than asthma; current diagnosis of vasculitis; cirrhosis or current unstable liver or biliary disease.
Interventions
N=252 depemokimab (at a dose of 100 mg SC at weeks 0 and 26 plus standard care).
N=128 placebo (matching placebo at weeks 0 and 26 plus standard care).
Primary outcome
Annual rate of exacerbations at week 52
0.56
1.08
1.1
0.8
0.5
0.3
0.0
Depemokimab
Placebo
Significant
decrease ▼
Significant decrease in annual rate of exacerbations at week 52 (0.56 vs. 1.08; RR 0.52, 95% CI 0.36 to 0.73).
Secondary outcomes
No significant difference in reduction in St. George's Respiratory Questionnaire score at week 52 (14.8 points vs. 12.49 points; AD 2.31 points, 95% CI -1.23 to 5.84).
No significant difference in reduction in Asthma Control Questionnaire-5 score at week 52 (0.81 points vs. 0.7 points; AD 0.11 points, 95% CI -0.11 to 0.33).
No significant difference in improvement in prebronchodilator FEV1 at week 52 (0.24 L vs. 0.18 L; AD 0.06 L, 95% CI -0.04 to 0.15).
Safety outcomes
No significant difference in adverse events.
Conclusion
In patients with severe eosinophilic asthma, depemokimab was superior to placebo with respect to annual rate of exacerbations at week 52.
Reference
David J Jackson, Michael E Wechsler, Daniel J Jackson et al. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype. N Engl J Med. 2024 Sep 9. Online ahead of print.
Open reference URL